Skip to content

Analisis of Facors Involved in Antidepressant Treatment Response of Major Depressive Disorder

Treatment Response Study of Sertraline to Treat Japanese Major Depressive Disorder

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01454635
Acronym
AFADTRMDD
Enrollment
96
Registered
2011-10-19
Start date
2008-06-30
Completion date
2010-03-31
Last updated
2011-10-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Major Depressive Disorder

Keywords

depression, treatment response, selective serotonin reuptake inhibitor

Brief summary

The purpose of this study is to predict and visualize sertraline treatment response in major depressive disorder with clinical symptoms, demographic and stress state, personality, eight genetic polymorphisms at baseline.

Detailed description

While only about 50% of patients respond to first treatment in major depressive disorder, 30-40% did not remit after continuous 1 year treatment. However, patients must remain on their prescribed medications for at least 4 weeks without knowing whether the particular antidepressant will be effective. Studies have suggested a number of predictors of treatment response, but varying degrees of success and nearly all with poor prognostic sensitivity and specificity. The investigators investigated clinical symptoms, demographic and stress state, personality and genetic polymorphisms in patients of major depressive disorder treated with sertraline and performed multivariate analysis to extract the predicting factors. Moreover, the investigators tried to visualize weight of variables and pathway one another.

Interventions

DRUGSertraline

dosage,frequency and duration

Sponsors

Showa University
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
20 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* clinical diagnosis of Major Depressive Disorder * Must be able to swallow tablets

Exclusion criteria

* pregnant * breastfeeding

Design outcomes

Primary

MeasureTime frame
Hamilton Rating Scale for Depression8 weeks

Countries

Japan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026